OOIR: Observatory of International Research

Papers

(The TQCC of Lancet HIV is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Optimising anal cancer screening through risk stratification	322
Lenacapavir: an attractive option, but proceed with caution	157
Risk estimation in HIV reveals our usual blind spots	146
Controversial chronicler of LGBTQ rights	114
A moment of reckoning	112
Are we ready for long-acting HIV treatment for adolescents?	104
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	103
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	99
Correction to Lancet HIV 2022; 9: e791–800	91
How do we prevent anal cancer in people living with HIV?	86
The Australian AIDS crisis through the eyes of volunteers	83
HIV and COVID-19: juxtaposition of two pandemics	81
Evidence supports use of on-demand PrEP for HIV prevention	80
Lung cancer in people living with HIV	79
Transplant donation without discrimination	77
Argentina updates HIV laws	65
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	62
How much could long-acting PrEP cost in South Africa?	59
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	58
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	58
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	57
Steps toward quick and equitable roll-out of lenacapavir	56
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	55
All roads lead to Westminster: the infected blood scandal	54
Redefining care: injectable HIV treatment for adolescents	52

The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	52
Making America unhealthy again	52
Recent gay Black history in the UK	51
Reducing HIV transmission in British Columbia, Canada	50
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	48
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	48
Sex as a biological variable in HIV-1 and schistosome co-infection	46
A public health approach to drug use crucial to ending AIDS	46
Equitable access to long-acting PrEP on the way?	45
Game-changing study of second-line HIV treatment	45
Gains and gaps: addressing HIV in diverse sex worker groups	44
Unheard testimony	44
Dolutegravir in neonates: finally we are getting there!	43
Stigma reduction is key to improving the HIV care continuum	43
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	43
Suicide prevention research is crucial to achieving health equity for people with HIV	43
WHO recommends lenacapavir for HIV prevention	42
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	41
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	40
Fate of people with HIV in jeopardy in Ukraine	40
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	39
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	38
Integration of sexual health and HIV services	38
An eventful conference	38
How can Africa sustain its HIV response amid US aid cuts?	36
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	35
Use of WHO paediatric weight-band dosing in drug labels	35
The impact of cuts in the US President's Emergency Plan for AIDS Relief funding for HIV pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	35
HIV self-testing: from availability to strategic deployment	34
Preventing sexually transmitted infections in the age of PrEP	33
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	33
PEPFAR: promises and pitfalls	33
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	33
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial	33
Patterns of post-partum HIV care engagement	33
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	33
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	33
Eliminating HIV in the UK among men who have sex with men	33
Advancing the prevention and treatment of HIV in children: priorities for research and development	32
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	32
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	32
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	30
Reduction of HIV reservoir after stem cell transplantation	30
Highlights from the 25th International AIDS Conference	29
Effects of self-testing on HIV outcomes in west Africa	28
Coffee with IAS President Beatriz Grinsztejn	27
Second-line HIV treatments for adults in LMICs	27
Addressing partner violence to end infant HIV infection	27
Closing the gap to UNAIDS 95-95-95: Lesotho's success story	26
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	26

Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	24
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	24
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	24
Metabolic implications and safety of dolutegravir use in pregnancy	24
Implementation of PrEP in Latin America	23
Crucial need for improved pharmacovigilance in pregnancy	23
Can treatment-as-prevention and PrEP reduce HIV incidence?	22
Optimised second-line regimens in the public health approach	22
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	22
HIV-free generation within reach for Botswana	22
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	21
No woman left behind: achieving cervical cancer elimination among women living with HIV	21
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	21
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	20
Correction to Lancet HIV 2025; 12: e691–700	20
Complex response to HIV and tuberculosis in South Sudan	20
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	20
Intersectional climate justice, health equity, and HIV	20
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	19
Need for clear inclusion criteria in reviews of antiretroviral treatments	19
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	19
The HIV vaccine quest: ethical and implementation challenges	19
A field of possibilities for paediatric HIV	19
Treatment of HIV and HBV coinfection	19
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	18
Can COVID-19 changes reduce stigma in African HIV clinics?	18
Point-of-care testing to achieve paediatric 95-95-95 targets	18
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	18
Breast cancer survival in women living with HIV	18
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	18
Making PrEP easy	18
Integrase inhibitors hand us a new HIV clinical puzzle	18
Unified health surveys for integrated health systems	17
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	17
HERO—providing support for those engaged in chemsex	17
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	17
Thank you to The Lancet HIV's clinical and statistical peer reviewers in 2021	17
HIV treatment in Russia on the brink of crisis	17
Long-acting PrEP for adolescent girls and young women	17
Realising long-acting ART as first-line treatment	17
A new index to guide global drug policies	17
Activists step in to deliver PEP and PrEP in Mexico	16
Non-communicable diseases in older people living with HIV in four African countries: a cohort study	16
Critical illness due to infection in people living with HIV	16
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	15
Expanding options of child-friendly, single-tablet regimens for young children with HIV	15
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	15
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	15
A career dedicated to public service	15
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	15
Improving outcomes for children in families with HIV	15
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	14
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	14
Correction to Lancet HIV 2023; 10: e424–26	14
Inherited fear: 40 years of HIV/AIDS in the UK	14
Tajikistan faces a crucial moment in HIV/AIDS response	14
Expanding PrEP treatment options with a potent anti-HIV antibody	14
HIV-related CNS infections: translating DREAMM into reality	13
Forgiveness of an intermittent HIV treatment strategy	13
A research framework to support re-engagement and continuous engagement in HIV care	13
HIV viral suppression is key to healthy longevity	13
Ending HIV in Chicago by 2030	13
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	13
Correction to Lancet HIV 2025; 12: e473–84	13
PEPFAR reauthorisation hangs in the balance	13
Zvandiri—when medicines alone are not enough	13
Increased risk of mental illness in people with HIV	13
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	13
Where does doravirine fit in current antiretroviral therapy?	12
Home delivery of ART: could this be a reality in South Africa?	12
Real-world safety of pre-exposure prophylaxis for HIV	12
Screening for chlamydia and incidence of symptomatic infections	12
Equitable access to PrEP is essential to reap its benefits	12
Reimagining HIV prevention with artificial intelligence	12
What future for HIV vaccines?	12
Mexican perspective on the Mosaico HIV vaccine trial	12
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	11
Long-acting PrEP: new opportunities with some drawbacks	11
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	11
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	11

Defining principles for a choice-based approach to HIV prevention	11
UK and US militaries update HIV policies	11
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	11
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	11
COVID-19 antivirals must not affect HIV drug supply	11
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	10
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-	10
Expansion of PrEP and PEP services in China	10
Legislation threat to services for LGBTQ+ people in Georgia	10
Response to Thailand's commitment to support community-led HIV services	10
Putting people first in communication about HIV	10
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	10
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	10
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	10
Low-cost point-of-care urine test to enhance PrEP adherence	10
Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua	9
Russia spiralling into an HIV crisis	9
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	9
CD4 cell counts at HIV diagnosis in the Eastern Mediterranean Region	9
Due south: navigating volatile health research landscapes	9
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era	9
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial	9
Do we need routine integrase resistance testing before starting antiretroviral therapy?	9
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	9
Artificial intelligence in HIV research, policy, and clinical care	9
The urgent need for opioid agonist treatment in Russia	8
Use of mobile phone data in HIV epidemic control	8
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of	8
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	8
Closeted life of a Hollywood giant	8
Acceptability, feasibility, and effectiveness of caregiver-assisted HIV self-testing among children using an oral mucosal test in Uganda and Zambia: a prospective interventional study	8
Dolutegravir dosing with rifampicin	8
HIV epidemiology in the WHO Eastern Mediterranean region: a multicountry programme review	8
Elton John AIDS Foundation plugging gaps in HIV funding	8
Mental health needs of adolescents with HIV in Africa	8
Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries	8
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	8
COP27 Climate Change Conference: urgent action needed for Africa and the world	8
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	8
Understanding and managing disordered sleep in people with HIV	8
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	8